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INTERNATIONAL CONFERENCE  
“TUMOR AND HOST: NOVEL ASPECTS OF OLD PROBLEM”
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine,  
Kyiv 03022, Ukraine
The International Conference “Tumor and Host: 
Novel Aspects of Old Problem” dedicated to the 50th 
anniversary of RE Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology (IEPOR) of Na­
tional Academy of Sciences of Ukraine (NASU) was 
held during September 21–24, 2010 in Kiev, Ukraine. 
It was organized by IEPOR, and passed under patron­
age of the President of Ukraine Viktor Yanukovich.
The Scientific Program covered the most important 
topics of cancer research and was divided into five 
Sessions: 
1. “Tumor Biology and Immunology” that focused 
on the basic aspects of tumor biology and immunology 
in a single issue framework. Topics included mecha­
nisms that determined metastasis and homing of tumor 
cells, tumor angiogenesis and lymphangiogenesis, the 
biology and molecular biology of cancer stem cells, im­
munological aspects of tumor – host interaction.
2. “Metabolic and Stromal Microenvironment 
of Tumor Cells” that focused on the tumor micro­
environment as a key factor in tumor development 
and progression. Topics included hypoxia signaling, 
angiogenesis and aerobic glycolysis in human tumors 
as a basis for diagnostics and anticancer strategies. 
Key questions which were discussed: 1) Inflammation 
and cancer: what is common and what is different? 
2) Tumor hypoxia impact on tumor – host interaction: 
a main regulator of malignant process outcome?
3. “Tumor markers: Signaling, Diagnosis and Prog­
nosis” that covered fundamental and practical aspects 
of tumor markers: identification of novel tumor markers, 
peculiarity of signal transduction pathways in tumor 
cells, application of tumor markers and cell differentia­
tion antigens for cancer diagnosis and prognosis.
4. “Mechanism of Carcinogenesis and Cancer 
Prevention” that focused on underlying mechanisms 
of tumorigenesis and cancer prevention. Special em­
phases were given: a) addressing the role of genetic and 
epigenetic alterations and their interactions in cancer 
development; and b) novel approaches for development 
of sensitive and reliable biomarkers for early detection 
and prevention of cancer, including nutrition.
5. “Cancer Therapy: New Technologies, Biothe­
rapy, Individualization” that covered the clinical and 
experimental investigations of cancer therapeutics 
mediated through tumor – host interactions (bio­
therapy, vascular disruptive therapy, etc.), validation 
of new targets for cancer therapy and new strategies 
for delivering therapy to tumors.
The Conference was officially opened by Presi­
dent of the National Academy of Sciences of Ukraine 
academician Boris E. Paton. The scientific part of the 
meeting was started by academician Vasyl F. Chekhun 
(IEPOR NASU, Kyiv, Ukraine) with lecture “The Concept 
Tumor and Host in the Post­Genomic Era” followed 
by lecture “The Cancer Epigenome and Epigenetic 
“Therapy” of Peter A. Jones (University of Southern 
California/Norris Comprehensive Cancer Center, Los 
Angeles, CA, USA).
Prof. P. Vaupel (Technical University of Munich, 
Germany) presented the plenary lecture “Metabolic 
microenvironment of tumor cells: a key factor in ma­
lignant progression” and accented attention on the 
impact of relevant pathophysiological factors, such 
as chronic and fluctuating tissue hypoxia or anoxia, 
acidosis, nutrient deprivation, energy depletion, 
 elevated vascular permeability and high interstitial fluid 
pressure on tumor growth and malignant progression. 
Prof. H. Friess (Technical University of Munich, 
Germany) in the plenary lecture “Surgical procedure 
as an inducer of tumor angiogenesis” discussed the 
problem of surgical resection in the light of well known 
fact that the healing process following surgery neces­
sitates extensive angiogenesis, which can be a clinical 
challenge due to its tumor­promoting effect. It was 
suggested that initiation of anti­angiogenesis thera­
pies may be used for the early postoperative period 
before the start of conventional chemotherapy.
Prof. G. Klein (Karolinska Institutet, Stockholm, 
Sweden) presented a plenary lecture “Intercellular 
surveillance against cancer” and decided to look for 
variation in cancer resistance in humans, focusing 
on one particular mechanism of resistance, namely 
microenvironmental control (also called intercellular 
surveillance). It was established that high throughput 
system allows the quantitative analysis of the inhibitory 
effect of fibroblasts on the population level and the 
exploration of differences depending on the source 
of the normal cells.
Prof. E. Klein (Karolinska Institutet, Stockholm, Swe­
den) presented a plenary lecture “EBV causes mono­
nucleosis, a common disease, but it was discovered 
in a rare lymphoma”. It was discussed in the accordance 
of recent studies that EBV­encoded proteins can inhibit 
myc induced apoptosis. Author has shown that the SAP 
protein expressed in lymphocytes has a proapoptotic 
function and assumed that the constitutively activated 
myc can induce proliferation in such B lymphocytes 
that lack SAP, while the myc translocation can induce 
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proliferation in EBV carrying cells even if they express 
SAP because EBNA­1 inhibits apoptosis.
Prof. M. Horsman (Aarhus University, Denmark) 
concentrated on the tumor vasculature and vascular 
targeting therapy and discussed significance two 
forms of vascular targeting agents (VTAs): those 
that inhibit the angiogenesis process (angiogenesis 
inhibitors; AIs) and those that damage the already es­
tablished vessels (vascular disrupting agents; VDAs).
Prof. J. Kleeff (Technical University of Munich, Ger­
many) focused on the role of tumor microenvironment 
in pancreatic cancer development and progression 
and suggested to target the activated stroma in order 
to uncouple epithelial­stromal interactions to interrupt 
multiple aberrant autocrine and paracrine pathways 
that promote pancreatic cancer cell growth, invasion, 
metastasis, and angiogenesis.
Prof. S. Osinsky (IEPOR NASU, Kyiv, Ukraine) 
discussed the tumor cell microenvironment as a ma­
chinery for tumor­host interaction and presented 
recent data allowing to suggest that metabolic micro­
environment of tumor cells (hypoxia, low extracellular 
pH, low perfusion and high interstitial fluid pressure) 
is a key factor determining the character and direction 
of tumor­host interactions.
Prof. A. Sica (Fondazione Humanitas per la Ricerca, 
Milan, Italy) discussed the role of tumor­associated 
macrophages (TAM) in cancer­related inflammation 
and suggested that the development of effective 
strategies to tip the balance by blocking cancer pro­
moting inflammation and/or activating protective in­
nate immunity may require definition of actors at play 
at different anatomical sites and in different tumors.
Prof. N. Berezhnaya (IEPOR NASU, Kyiv, Ukraine) 
discussed the aspects of interaction between tumor 
and immune system with special attention to the role 
of tumor cell biology and analyzed the involvement 
of cytokines, chemokines, lymphocytes, and tumor 
cells in the phenomenon of elevated sensitivity to LAK 
action that can be particularly mediated by decreased 
E­cadherin expression and increased CD40 expression.
Prof. M. Molls (Technical University Munich, 
Germany) presented data about imaging of tumor 
physiology through new methods of tumor visualization 
and accented that the number of questions are kept 
to be answered: How to assess 3­D­images of hypo­
xia? How to account for changes of hypoxia over time? 
How to assess the blood flow? What is a correlation 
between imaging and histopathology?
Dr. N. Volodko (D Galytsky National Medical Uni­
versity, Lviv, Ukraine) presented the data about the 
relationship between microvessels density, degree 
of macrophage infiltration, expression of TNF and TGFβ 
in human ovarian cancer and its chemosensitivity. 
Dr. A. Kovelskaya (IEPOR NASU, Kyiv, Ukraine) pre­
sented data about hypoxia and tumor­associated mac­
rophages (TAM) in human gastric cancer (GC) and their 
impact on malignant progression concluding that the 
severe tumor hypoxia and high TAMs are the para meters 
that are associated with tumor aggressiveness, and can 
be characterized as strong worse prognostic factors for 
GC independently from the type of tumor treatment.
Dr. B. Gerashchenko (IEPOR NASU, Kyiv, Ukraine) 
presented data on the hyperthermia effect of inter­
action of proteins of the Mre11 complex (composed 
of Mre11, Rad50 and Nbs1) that is involved in DSB 
repair. Dr. N. Florovskaya (Murmansk Oncological Hos­
pital, Russia) presented results of thermochemotherapy 
of colorectal cancer patients with liver metastases 
that improved the clinical outcome. Dr.  I. Ganusevich 
(IEPOR NASU, Kyiv, Ukraine) presented data about 
MMP­2 and  ­9 activities in tumor tissue and bone mar­
row in the connection with disseminated tumor cells 
as a prognostic factor for human gastric cancer outcome. 
Session 3 “Tumor Markers: signaling, diagnosis 
and prognosis” integrated conceptual reviews and 
scientific reports covering different levels of biomedi­
cal research: fundamental, translational research and 
applied studies. In the plenary lecture Prof. Ivan Gout 
(University College, London, UK) presented thorough 
overview of mTOR (mammalian target of rapamycin) 
signaling pathway in control of cell metabolism, 
growth and proliferation and also its role in oncogenic 
transformation. Tumor­associated changes in tran­
sctiptome (Prof. V.M. Kavsan, Institute of Molecular 
Biology and Genetics of NASU, Kyiv, Ukraine), pro­
teome (Dr. P.V. Belousov, Chair of Immunology, Fac­
ulty of Biology, Moscow State University, Moscow, Rus­
sia) and deregulation of transcription factors in tumor 
progression (Dr. N.L. Lazarevich, N.N. Blokhin Russian 
Cancer Research Center, Moscow, Russia) formed 
the block of lectures on molecular biology of tumors. 
The role of signal transduction pathways in regula­
tion of tumor cell biology was covered in lectures 
on receptor­mediated signaling in Hodgkin lymphoma 
cells (Drs. S.P. Sidorenko  and M. Yurchenko, IEPOR 
NASU, Kyiv, Ukraine) and the role of adaptor proteins 
in cancerogenesis (Prof. L.B. Drobot, Palladin Institute 
of Biochemistry of NASU, Kyiv, Ukraine). Presenta­
tions of Dr. V.O. Nadgornaya and Prof. D.F. Gluzman 
(IEPOR NASU, Kyiv, NASU) and also Dr. I.N. Kravchuk 
(Institute of Molecular Biology and Genetics of NASU, 
Kyiv, Ukraine) were devoted to leukemia markers, 
while Dr. N.T. Pande (Division of Gynecological Onco­
logy, Oregon Heath and Science university, USA) and 
Prof. V.V. Filonenko (Institute of Molecular Biology 
and Genetics of NASU, Kyiv, Ukraine) focused on new 
markers of ovarian cancer. It should be noted that 
oral and poster reports on translational and applied 
stu dies included evaluation of tumor cell molecular 
profile for prognosis and treatment individualization 
(Dr. N.Yu. Lukianova, IEPOR NASU, Kyiv, Ukraine), 
studies of mutant epidermal growth factor receptor and 
MDM2 expression in ependymomas (Dr. E.S. Galanta, 
Romodanov Institute of Neurosurgery, NAMSU, Kyiv, 
Ukraine) and methylation status in colorectal tumors 
(Dr. Gordiyuk, Institute of Molecular Biology and Ge­
netics of NASU, Kyiv, Ukraine), and others.
The number of lectures and reports were presented 
in the frame of Session 5. Prof. V.A. Shlyakhovenko 
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(IEPOR NASU, Kyiv, Ukraine) presented lecture on the in­
vestigation of anticancer activity of glycopeptidic cancer 
vaccine (GPV) and certain adjuvants against transplant­
able metastasizing and nonmetastasizing tumors.
Invited lecture of Prof. N.F. Gamaleia (IEPOR 
NASU, Kyiv, Ukraine) was devoted for the develop­
ment of new approaches to improve photodynamic 
therapy of malignant neoplasms, in particularly by the 
modern bionanothechnology approaches using nano­
composites, comprising both   photosensitizing agent 
and nanoparticles.
Dr. D.N. Kaluzhny (Institute of Molecular Biology 
of RAS, Moscow, Russia) gave the insight into con­
ventional and unusual DNA structures for anticancer 
drug design. 
Prof. V.G. Nikolaev (IEPOR NASU, Kyiv, Ukraine) 
presented results of long­term investigations aimed 
to use the methods of adsorptive therapy — hemo­
sorption, enterosorption and application sorption 
in oncologic practice with special attention on the new 
generation of highly active sorbents as well as new 
possibilities for the use of modern adsorptive tech­
nologies in clinical oncology.
The invited lecture of Dr. G.I. Solyanik (IEPOR 
NASU, Kyiv, Ukraine) was dedicated to multifactorial 
nature of tumor drug resistance, in particular tumor 
microenvironment (including tumor vascularization 
and extracellular matrix) that plays an important role 
in protecting cancer cells from initial drug exposure.
Prof. B.T. Bilynskyi (D. Galytsky National Medical 
University, Lviv, Ukraine) in the invited lecture dis­
cussed the influence of fundamental investigations 
in biology and oncology on the clinical strategy and 
tactics at the example of the breast cancer.
Dr. S. Souchelnytskyi (Karolinska institutet, Stock­
holm, Sweden) presented data about role of proteome 
signatures of immortalization, acquisition of high 
proliferation potential in the formation of tumor and 
metastases, especially correlation between compo­
nents of the DRNet that provide a tool for diagnostics 
and personalized treatment.
The conference was attended by 259 leading 
experts of the experimental, clinical, medical, phar­
maceutical oncology, as well as students and gradu­
ate students of Universities and Research Institutes 
of Ukraine, near and far abroad. The scientists from 
14 countries were represented by 30 Academic and 
24 Educational institutions. The media sector, in par­
ticular television, radio, and newspapers has high­
lighted the work of conference. Public and government 
organizations including international ones have also 
attended the conference.  
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